VerifiedFreedom Diagnostics
99.92%
Purity
Passed full QC panel
- Variant
- Retatrutide 10mg
- Lot
- R1001
- Net Peptide Content
- 11.74 mg
- Endotoxin
- Passed
- Heavy Metals
- Passed
- Lab
- Freedom Diagnostics
← Back to Research Library
Valence Labs Research
Retatrutide
Metabolic Research Peptide
- Compound
- Retatrutide
- Category
- Research Peptide
- Available Variant
- 10mg
- Research Status
- Research Use Only
Overview
Retatrutide is an investigational peptide that activates three metabolic receptor pathways: GIP, GLP-1, and glucagon receptors. This triple-receptor activity has made it an important subject of metabolic research.
Human clinical studies have investigated retatrutide in areas including body-weight regulation, glucose metabolism, energy balance, body composition, and broader cardiometabolic markers. Retatrutide remains an investigational compound and continues to be evaluated in clinical development.
Research Areas
Triple-Receptor Signaling
Retatrutide is studied for its combined activity at GIP, GLP-1, and glucagon receptors and how signaling across these pathways affects metabolic regulation.
Body-Weight Regulation
Clinical research has examined changes in body weight and related measurements during retatrutide treatment.
Glucose & Metabolic Regulation
Research has evaluated glucose-related and broader metabolic responses associated with its multi-receptor activity.
Energy Balance
The glucagon, GIP, and GLP-1 pathways are involved in different aspects of energy intake, expenditure, and metabolic signaling, making energy balance an important area of retatrutide research.
Cardiometabolic Research
Clinical studies have also examined lipid, inflammatory, and other cardiometabolic markers.
How It Is Being Studied
Retatrutide has progressed through randomized human clinical trials and is being evaluated in Phase 3 clinical development. This gives retatrutide a substantially larger human evidence base than many experimental research peptides.
Research remains ongoing, and findings from clinical trials should not be interpreted as guaranteed outcomes from a research product.
Specifications
Catalog details for this product.
- Product Name
- Retatrutide
- Category
- Research Peptide
- Variant
- 10mg
- Form
- Documentation pending
- Storage
- Documentation pending
- Purity
- Documentation pending
- Intended Use
- Laboratory research use only
Available Documentation
Certificates of Analysis
VerifiedFreedom Diagnostics
99.63%
Purity
Passed full QC panel
- Variant
- Retatrutide 20mg
- Lot
- R2001
- Net Peptide Content
- 23.12 mg
- Endotoxin
- Passed
- Heavy Metals
- Passed
- Lab
- Freedom Diagnostics
VerifiedFreedom Diagnostics
99.71%
Purity
Passed full QC panel
- Variant
- Retatrutide 30mg
- Lot
- R3001
- Net Peptide Content
- 30.32 mg
- Endotoxin
- Passed
- Heavy Metals
- Passed
- Lab
- Freedom Diagnostics
References
- Jastreboff et al. — Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial
New England Journal of Medicine
- PubMed / clinical literature on retatrutide Phase 2 obesity research
- TRIUMPH Clinical Development Program — Retatrutide Phase 3 Trial Design
PubMed
Available Product
Retatrutide
10mg